Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial
Movement Disorders · 2024-09 · 39 (9) · 1533-1543
DOI: 10.1002/mds.29878 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 08.06.2024. Verfasst von Christine Brefel-Courbon und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre, Centre d'Investigation Clinique CIC1436, University Hospital of Toulo…. Hauptthemen laut MEDLINE: Oxycodone, Levodopa, Parkinson Disease, Benserazide. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The French Ministry of Health.
Abstract (Originalsprache)
Background
Among the different types of pain related to Parkinson's disease (PD), parkinsonian central pain (PCP) is the most disabling.
Objectives
We investigated the analgesic efficacy of two therapeutic strategies (opioid with oxycodone‐ prolonged‐release (PR) and higher dose of levodopa/benserazide) compared with placebo in patients with PCP.
Methods
OXYDOPA was a randomized, double‐blind, double‐dummy, placebo‐controlled, multicenter parallel‐group trial run at 15 centers within the French NS‐Park network. PD patients with PCP (≥30 on the Visual Analogue Scale [VAS]) were randomly assigned to receive oxycodone‐PR (up to 40 mg/day), levodopa/benserazide (up to 200 mg/day) or matching placebo three times a day (tid) for 8 weeks at a stable dose, in add‐on to their current dopaminergic therapy. The primary endpoint was the change in average pain intensity over the previous week rated on VAS from baseline to week‐10 based on modified intention‐to‐treat analyses.
Results
Between May 2016 and August 2020, 66 patients were randomized to oxycodone‐PR (n = 23), levodopa/benserazide (n = 20) or placebo (n = 23). The mean change in pain intensity was −17 ± 18.5 on oxycodone‐PR, −8.3 ± 11.1 on levodopa/benserazide, and −14.3 ± 18.9 in the placebo groups. The absolute difference versus placebo was −1.54 (97.5% confidence interval [CI], −17.0 to 13.90; P = 0.8) on oxycodone‐PR and +7.79 (97.5% CI, −4.99 to 20.58; P = 0.2) on levodopa/benserazide. Similar proportions of patients in each group experienced all‐cause adverse events. Those leading to study discontinuation were most frequently observed with oxycodone‐PR (39%) than levodopa/benserazide (5%) or placebo (15%).
Conclusions
The present trial failed to demonstrate the superiority of oxycodone‐PR or a higher dose of levodopa in patients with PCP, while oxycodone‐PR was poorly tolerated. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Centre, NS-PARK/FCRIN Network, Toulouse, France.
- Toulouse Neuroimaging Centre (TONIC), UMR1214 INSERM/UT3, Toulouse, France.
- Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, CNRS, IGCCN, Institut Pascal, NS-PARK/FCRIN Network, Aubière, France.
- Department of Medical Pharmacology, Expert Centre of Parkinson's Disease, University of Lille, LilNCog, Lille Neuroscience and Cognition, Inserm, INSERM UMR-S1172, CHU de Lille LICEND COEN Center Lille NS-Park Network,…
- Department of Clinical Pharmacology, Methodology Data management and Statistical Analysis Unit, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, Toulouse, France.
- Department of Neurology, Rouen University Hospital and University of Rouen, Mont-Saint-Aignan, France.
ORCID-Profile: Christine Brefel-Courbon, Ana Marques, Fabienne Ory-Magne, Jean Christophe Corvol, Olivier Rascol
Förderung
- The French Ministry of Health
Zitieren
APA
Brefel-Courbon, C., Harroch, E., Marques, A., Devos, D., Thalamas, C., Rousseau, V., Ory-Magne, F., Fabbri, M., Maltête, D., Rouaud, T., Drapier, S., Tir, M., Thobois, S., Salhi, H., Corvol, J. C., Castelnovo, G., Lagha-Boukbiza, O., Fluchère, F., Frismand, S., …, & Rascol, O. (2024). Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial. Movement Disorders, 39(9), 1533-1543. https://doi.org/10.1002/mds.29878
Vancouver
Brefel-Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, et al. Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial. Movement Disorders. 2024;39(9):1533-1543. doi:10.1002/mds.29878
BibTeX
@article{BrefelCourbon2024,
author = {Brefel-Courbon, Christine and Harroch, Estelle and Marques, Ana and Devos, David and Thalamas, Claire and Rousseau, Vanessa and Ory-Magne, Fabienne and Fabbri, Margherita and Maltête, David and Rouaud, Tiphaine and Drapier, Sophie and Tir, Melissa and Thobois, Stephane and Salhi, Hayet and Corvol, Jean Christophe and Castelnovo, Giovanni and Lagha-Boukbiza, Ouhaid and Fluchère, Fréderique and Frismand, Solene and Ansquer, Solene and Sommet, Agnes and Rascol, Olivier},
title = {Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {9},
pages = {1533--1543},
doi = {10.1002/mds.29878}
}
EUVIMED